EMPASHILD M 12.5/500 10S

About

EMPASHILD M 12.5/500 is a fixed-dose combination medication containing Empagliflozin 12.5mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, an SGLT2 inhibitor, lowers blood glucose by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. Metformin, a biguanide, reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues. This combination provides a comprehensive approach to glycemic control by addressing multiple pathophysiological defects of type 2 diabetes. It not only helps to significantly reduce HbA1c but also offers additional benefits such as weight management and cardiovascular protection, making it a robust option for patients requiring multifaceted glycemic control.

Uses

• To improve glycemic control in adults with type 2 diabetes mellitus.
• Used as an adjunct to diet and exercise.
• For patients inadequately controlled on metformin, or empagliflozin, or both.
• May reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Directions For Use

Take this medication orally, usually twice daily with meals, as prescribed by your healthcare provider. Swallow the tablet whole with water.

Benefits

• Comprehensive blood glucose control through two distinct mechanisms.
• Significant reduction in HbA1c levels.
• Potential for modest weight loss.
• May offer cardiovascular and renal protective benefits.
• Improved insulin sensitivity and reduced glucose production.
• Low risk of hypoglycemia when used alone.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Urinary tract infections
• Genital yeast infections
• Increased urination
• Metallic taste in mouth
• Headache
• Dizziness
• Fatigue
• Dehydration
• Lactic acidosis (rare, serious)

Safety Measures

• Alcohol - Avoid excessive alcohol intake as it can significantly increase the risk of lactic acidosis, especially with metformin, and may also increase the risk of dehydration.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters, due to potential adverse effects on fetal kidney development. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and could affect the infant. Consult your doctor.
• Liver - Use with caution in patients with liver impairment, particularly with metformin, due to increased risk of lactic acidosis. Not recommended in severe hepatic impairment.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustments are necessary for moderate renal impairment, and empagliflozin efficacy is reduced with declining renal function.
• Lung - Severe acute or chronic lung disease leading to hypoxia can increase the risk of lactic acidosis, especially with metformin. Use with caution.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.